Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: A meta-analysis

Carcinogenesis

Volumn 31, Issue 4, 2010, Pages 643-647

  Hu, Zheng ^a   Li, Xiang ^a   Qu, Xincai ^b   He, Yungang ^c   Ring, Brian Z ^d   Song, Enmin ^b   Su, Li ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Chinese Academy of Sciences   (China)

^d Applied Genomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; GENE DUPLICATION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; INDEL MUTATION; INTRON; LUNG CANCER; PRIORITY JOURNAL; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; NEOPLASM; PUBLISHING; TUMOR SUPPRESSOR GENE;

GENE DUPLICATION; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRONS; NEOPLASMS; POLYMORPHISM, GENETIC; PUBLICATION BIAS;

EID: 77950906345     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq018     Document Type: Article

References (42)

1. Vogelstein, B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
2. Vousden, K.H. et al. (2007) p53 in health and disease. Nat. Rev. Mol. Cell Biol., 8, 275-283.
3. Whibley, C. et al. (2009) p53 polymorphisms: cancer implications. Nat. Rev. Cancer, 2, 95-107.
4. Pietsch, E.C. et al. (2006) Polymorphisms in the p53 pathway. Oncogene, 25, 1602-1611.
5. Hrstka, R. et al. (2009) Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J. Cell. Mol. Med., 13, 440-453.
6. Ara, S. et al. (1990) Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res., 18, 4961.
7. Dumont, P. et al. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet., 33, 357-365.
8. Pim, D. et al. (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer, 108, 196-199.
9. Salvioli, S. et al. (2005) p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle, 4, 1264-1271.
10. Siddique, M. et al. (2006) Trp53-dependent DNA repair is affected by the codon 72 polymorphism. Oncogene, 25, 3489-3500.
11. Hu, Z. et al. (2009) Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res. Treat., Aug 6. [Epub ahead of print].
12. Lazar, V. et al. (1993) Simple sequence repeat polymorphism within the p53 gene. Oncogene, 8, 1703-1705.
13. Weston, A. et al. (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol. Biomarkers Prev., 6, 105-112.
14. Wang-Gohrke, S. et al. (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics, 12, 269-272.
15. De Vecchi, G. et al. (2008) The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCAmutation negative familial cases. Cancer Detect. Prev., 32, 140-143.
16. Gemignani, F. et al. (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 23, 1954-1956.
17. Perfumo, C. et al. (2006) Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion, 74, 228-235.
18. Wu, X. et al. (2002) p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl Cancer Inst., 94, 681-690.
19. Birgander, R. et al. (1995) P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis, 16, 2233-2236.
20. Mitra, S. et al. (2005) Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int. J. Cancer, 117, 786-793.
21. Mitra, S. et al. (2005) Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J. Clin. Pathol., 58, 26-31.
22. Tan, X.L. et al. (2007) Genetic polymorphisms in TP53, nonsteroidal antiinflammatory drugs and the risk of colorectal cancer: evidence for geneenvironment interaction? Pharmacogenet. Genomics, 17, 639-645.
23. Woelfelschneider, A. et al. (2008) A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis, 29, 1758-1764.
24. DerSimonian, R. et al. (1986) Meta-analysis in clinical trials. Control Clin. Trials, 7, 177-188.
25. Mantel, N. et al. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst., 22, 719-748.
26. Esteller, M. et al. (1997) Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br. J. Cancer, 75, 1385-1388.
27. Wang-Gohrke, S. et al. (1999) Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br. J. Cancer, 81, 179-183.
28. Suspitsin, E.N. et al. (2003) Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int. J. Cancer, 103, 431-433.
29. Schabath, M.B. et al. (2006) Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 15, 158-161.
30. Buyru, N. et al. (2007) p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect. Prev., 31, 207-213.
31. Chen, K. et al. (2007) Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin. Cancer Res., 13, 4300-4305.
32. Wang, W. et al. (2007) Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin. Cancer Res., 13, 5974-5981.
33. Ye, Y. et al. (2008) Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, 112, 2467-2474.
34. Akkiprik, M. et al. (2009) Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol. Oncol. Res., 15, 359-68.
35. Cavallone, L. et al. (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer, 8, 96.
36. Costa, S. et al. (2008) Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer, 8, 32.
37. Gaudet, M.M. et al. (2008) Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res. Treat., 108, 93-99.
38. Ashton, K.A. et al. (2009) Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol. Oncol., 113, 109-114.
39. De Feo, E. et al. (2009) A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat. Res., 675, 60-65.
40. Polakova, V. et al. (2009) Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum. Mutat., 30, 661-668.
41. Khrunin, A.V. et al. (2005) p53 polymorphisms in Russia and Belarus: correlation of the 2-1-1 haplotype frequency with longitude. Mol. Genet. Genomics, 272, 666-672.
42. Marcel, V. et al. (2009) TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J. Med. Genet., 46, 766-772.